NOTICE OF UPGRADE
Our websites will be unavailable between the hours of AEST 4AM September 17, 2022 and AEST 11PM on date September 18, 2022
SEARCH LISTED COMPANY
Any AUS or NZ company
SEARCH PRIVATE COMPANY
SEARCH FUNDS
Find any Australian or New Zealand company or fund (dead or alive) by using SEARCH above or go directly to the site:
|
|
06 October 2024
| Name: | PARADIGM BIOPHARMACEUTICALS LIMITED.. (PAR) |
| ISIN: | AU000000PAR5 |
| Date of Listing: | 19 August 2015 |
Stock Exchange Status: (updated daily)
This entity is currently listed and quoted on the Australian Securities Exchange.Legal Status: (updated monthly)
ACN: 169 346 963ABN: 94 169 346 963
Registration Date: 02 May 2014
Capital Gains Tax (CGT) Status: (updated at least quarterly)
To crystallise a capital gain or capital loss on your securities in this entity, you are able to sell your securities on-market in the normal manner. If you determine that the market in your securities is illiquid and you still wish to crystallise a capital gain or loss, kindly contact deListed at admin@delisted.com.au for suggestions as to how you might proceed.
Updates, corrections, disagreements please email to admin@delisted.com.au
Further information: deListed and InvestoGain are operated by Investogain Pty Limited which is licensed by ASIC as an Australian Financial Services Licensee (AFSL 334036). deListed acquires only securities that it deems to be of little or no value, in circumstances where the holder is unable to sell their securities on-market in the normal manner. This service has been provided online via the company’s website www.delisted.com.au since 2004.
Getting advice: Information provided in this section is of a general nature and applicable only to Australian tax residents who hold their investments on capital account (ie for long-term investment purposes). It has been prepared without taking into account your financial needs or tax situation. Before acting on the information, deListed suggests that you consider whether it is appropriate for your circumstances and recommends that you seek independent legal, financial, or taxation advice.
Disclaimer: The information provided above is to the best of our knowledge accurate as of today. But you should bear in mind that it is of a general nature and does not constitute financial or tax advice. Investogain Pty Limited accepts no liability for any loss arising from reliance on this information, including reliance on information that is no longer current.
Automic Registry Pty Ltd
Level 5, 191 ST GEORGES TERRACE PERTH WA 6000
Tel : +61 (2) 8072 1400 or 1300 288 664 (within Australia)
RegistryWebsite RegistryEmail
Expand this box to read and print
The suspension of trading in the options of Paradigm Biopharmaceuticals Limited will be lifted immediately. | 28/11/2023 |
The options of Paradigm Biopharmaceuticals Limited will be suspended immediately in accordance with Listing Rule 17.3, as there will be no deferred settlement trading. The options are expected to be quoted on a normal settlement basis on Tuesday, 28 November 2023. The suspension only applies to PAR's options and does not apply to any other quoted securities of PAR. | 21/11/2023 |
The suspension of trading in the securities of Paradigm Biopharmaceutics Limited will be lifted immediately, following the release by PAR of an announcement regarding the completion of a capital raising. | 08/04/2020 |
Bids received significantly exceeded the size of the placement. PAR fully funded to Phase 3 OA trial completion and readout. Support from large Australian and International institutional investors. Significant endorsement of PAR and its treatment of OA. Capital raising enables PAR to be focused on the clear path to regulatory approval and commercialisation. | 08/04/2020 |
The company releases a notice of Proposed issue of Securities - PAR. | 08/04/2020 |
The company will host a conference call at 8:30am (AEST) Wednesday 8th April to discuss the recent minutes provided by the US FDA and guidance over the requirements for the Phase 3 clinical trial design and NDA submission. The company will also discuss the recent SAS data on 34 patients who have been treated using the Phase 3 material and measured with the same endpoints that will be used in the Phase 3 clinical trials. Investors are encouraged to send through questions by 8:00pm (AEST) Tuesday 7th April, with the company collating questions sent and will endeavour to answer the most frequently asked. Questions are to be submitted to investorrelations@paradigmbiopharma.com. | 07/04/2020 |
Paradigm reports very encouraging real-world data ahead of its phase 3 OA clinical trial using the Phase 3 product and two Phase 3 endpoints. | 06/04/2020 |
The company receives clarity on US regulatory pathway. The pre-IND meeting was both positive and informative for Paradigm. The positive outcomes from the meeting were clear guidance around the primary and secondary endpoints for the Phase 3 clinical trial, the number of Phase 3 studies required for registration and overall clarity and guidance over the requirements for the Phase 3 clinical trial design and NDA submission. | 06/04/2020 |
The company releases its latest Corporate Presentation. | 06/04/2020 |
The securities of Paradigm Biopharmaceuticals Limited will be suspended from quotation immediately under Listing Rules 17.2, at the request of PAR, pending the release of an announcement regarding the proposed capital raising. | 06/04/2020 |
listed entity carried for record purposes only | 19/08/2015 |
The suspension of trading in the options of Paradigm Biopharmaceuticals Limited will be lifted immediately. | 28/11/2023 |
The options of Paradigm Biopharmaceuticals Limited will be suspended immediately in accordance with Listing Rule 17.3, as there will be no deferred settlement trading. The options are expected to be quoted on a normal settlement basis on Tuesday, 28 November 2023. The suspension only applies to PAR's options and does not apply to any other quoted securities of PAR. | 21/11/2023 |
The suspension of trading in the securities of Paradigm Biopharmaceutics Limited will be lifted immediately, following the release by PAR of an announcement regarding the completion of a capital raising. | 08/04/2020 |
Bids received significantly exceeded the size of the placement. PAR fully funded to Phase 3 OA trial completion and readout. Support from large Australian and International institutional investors. Significant endorsement of PAR and its treatment of OA. Capital raising enables PAR to be focused on the clear path to regulatory approval and commercialisation. | 08/04/2020 |
The company releases a notice of Proposed issue of Securities - PAR. | 08/04/2020 |
The company will host a conference call at 8:30am (AEST) Wednesday 8th April to discuss the recent minutes provided by the US FDA and guidance over the requirements for the Phase 3 clinical trial design and NDA submission. The company will also discuss the recent SAS data on 34 patients who have been treated using the Phase 3 material and measured with the same endpoints that will be used in the Phase 3 clinical trials. Investors are encouraged to send through questions by 8:00pm (AEST) Tuesday 7th April, with the company collating questions sent and will endeavour to answer the most frequently asked. Questions are to be submitted to investorrelations@paradigmbiopharma.com. | 07/04/2020 |
Paradigm reports very encouraging real-world data ahead of its phase 3 OA clinical trial using the Phase 3 product and two Phase 3 endpoints. | 06/04/2020 |
The company receives clarity on US regulatory pathway. The pre-IND meeting was both positive and informative for Paradigm. The positive outcomes from the meeting were clear guidance around the primary and secondary endpoints for the Phase 3 clinical trial, the number of Phase 3 studies required for registration and overall clarity and guidance over the requirements for the Phase 3 clinical trial design and NDA submission. | 06/04/2020 |
The company releases its latest Corporate Presentation. | 06/04/2020 |
The securities of Paradigm Biopharmaceuticals Limited will be suspended from quotation immediately under Listing Rules 17.2, at the request of PAR, pending the release of an announcement regarding the proposed capital raising. | 06/04/2020 |
listed entity carried for record purposes only | 19/08/2015 |
Your browser may reflect a date of printing in American format.
Purchases Sales
| DATE | DIRECTOR | NUMBER | PRICE | AMOUNT |
|---|---|---|---|---|
| 18/05/2023 | Helen Fisher | 10,204 | $0.982 | $10,020 |
| 12/05/2023 | Paul Rennie | 73,851 | $1.029 | $76,001 |
| 19/12/2022 | Paul Rennie | 47,720 | $1.289 | $61,521 |
| 08/03/2022 | Paul Rennie | 48,167 | $1.051 | $50,634 |
| 11/05/2020 | John Gaffney | -115,695 | $2.369 | $274,118 |
| NAME | TITLE | DATE OF APPT |
|---|---|---|
| Paul Rennie | Non Exec Chairman, Managing Director | 19/08/2015 |
| Jeannie Joughin | COO | 03/06/2020 |
| Abby Niven | CFO | 03/03/2023 |
| Amos Meltzer | Independent Director | 08/12/2020 |
| Matthew Fry | Non Exec Director | 04/03/2024 |
| Donna Skerrett | Executive Director, Interim CEO | 03/07/2020 |
| Abby Macnish | Company Secretary |
Date of first appointment, title may have changed.
| NAME | TITLE | DATE OF APPOINTMENT | DATE OF RESIGNATION |
|---|---|---|---|
| Helen Fisher | Non Exec Director | 11/02/2021 | 04/03/2024 |
| John Gaffney | Non Exec Director | 19/08/2015 | 20/10/2023 |
| Justin Cahill | CFO | 13/10/2020 | 03/03/2023 |
| Marco Polizzi | CEO | 01/07/2022 | 20/02/2023 |
| Chris Fullerton | Non Exec Director | 19/08/2015 | 20/11/2020 |
| Kevin Hollingsworth | CFO | 19/08/2015 | 13/10/2020 |
| Graeme Kaufman | Non Exec Chairman | 19/08/2015 | 24/06/2020 |
Date of first appointment, title may have changed.
Contact Us | Financial Services Guide | Privacy Policy
This website is owned and operated by Investogain Pty Limited.
ABN 88 129 443 447 | AFSL 334036
Information provided is of a general nature and not for trading or advice.
Copyright © 2002-2024 Investogain Pty Limited. All rights reserved.
